Junichi Kurebayashi    Department   Kawasaki University of Medical Welfare  ,    Position   Professor with Special Assignment
Article types	原著
Language	English
Peer review	Peer reviewed
Title	Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Journal	Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：02507005
Domestic / Foregin	Foregin
Volume, Issue, Page	40(5),pp.2475-2479
Author and coauthor	Yamamoto Jun, MurataTakuya, Sugisawa Norihiko, Higuchi Takashi, Tashiro Yoshihiko, Nishino Hiroto, Inubushi Sachiko, Sun YU, Lim Hyein, Miyake Kentaro, Shimoya Koichiro, Nomura Tsunehisa, Kurebayashi Junichi, Tanino Hirokazu, Hozumi Chihiro, Bouvet Michael, Singh Shree Ram, Endo Itaru, Hoffman Robert M
Publication date	2020/05
Summary	Abstract Background/aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. Materials and methods: The PDOX model was established in the left 2nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm3: G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. Results: The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Conclusion: Eribulin has clinical potential for triple-negative MPBC patients.
DOI	10.21873/anticanres.14217
PMID	32366391